129 related articles for article (PubMed ID: 35092070)
21. Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia.
Sakuma T; Sato K; Nagane Y; Mochida J; Sugimoto S; Ichinose T; Yamaguchi K; Uchiyama M; Takahashi S
Low Urin Tract Symptoms; 2010 Sep; 2(2):119-22. PubMed ID: 26676294
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of naftopidil for nocturia and consequent sleep disturbance in patients with benign prostatic hyperplasia].
Iwaki H; Narita M; Soga H; Sakano Y; Konishi T; Okada Y
Hinyokika Kiyo; 2010 Apr; 56(4):209-13. PubMed ID: 20448444
[TBL] [Abstract][Full Text] [Related]
23. [Correlation of IPSS with IL-8 and COX-2 levels in patients with benign prostatic hyperplasia and prostatitis].
Chen DA; Yang XZ; Zhang PH; Li GS; Chang DG
Zhonghua Nan Ke Xue; 2013 Jun; 19(6):527-30. PubMed ID: 23862231
[TBL] [Abstract][Full Text] [Related]
24. Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology.
Justulin LA; Acquaro C; Carvalho RF; Silva MD; Felisbino SL
Int J Androl; 2010 Jun; 33(3):489-99. PubMed ID: 19490185
[TBL] [Abstract][Full Text] [Related]
25. Col IV and Fn distribution in prostatic adenocarcinoma and correlation of 67LR, MMP-9 and TIMP-1 expression with Gleason score.
Işisağ A; Neşe N; Ermete M; Lekili M; Ayhan S; Kandiloğlu AR
Anal Quant Cytol Histol; 2003 Oct; 25(5):263-72. PubMed ID: 14603723
[TBL] [Abstract][Full Text] [Related]
26. Association of sleep quality with lower urinary tract symptoms/benign prostatic hyperplasia among men in China: A cross-sectional study.
Li Y; Zhou X; Qiu S; Cai B; Wang S; Chen L; Hu D; Jiang Z; Wang M; Xiong X; Jin K; Wei Q; Yang L; Ma L
Front Aging Neurosci; 2022; 14():938407. PubMed ID: 36353690
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical studies of the expression of matrix metalloproteinase-2 and metalloproteinase-9 in human prostate cancer.
Zeng H; Xiao Y; Lu G; Chen Y
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):373-4, 379. PubMed ID: 15015639
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
29. Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer.
Abdel-Meguid TA; Mosli HA; Al-Maghrabi JA
Saudi Med J; 2009 Dec; 30(12):1563-7. PubMed ID: 19936421
[TBL] [Abstract][Full Text] [Related]
30. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
[TBL] [Abstract][Full Text] [Related]
31. MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer.
Reis ST; Pontes-Junior J; Antunes AA; de Sousa-Canavez JM; Dall'Oglio MF; Passerotti CC; Abe DK; Crippa A; da Cruz JA; Timoszczuk LM; Srougi M; Leite KR
Int J Biol Markers; 2011; 26(4):255-61. PubMed ID: 22139647
[TBL] [Abstract][Full Text] [Related]
32. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Rademaker A; Lloyd GL; Gann P
J Urol; 2005 Oct; 174(4 Pt 1):1327-433. PubMed ID: 16145413
[TBL] [Abstract][Full Text] [Related]
33. [Relationship between interleukin-8 levels in expressed prostatic secretion and expressions of bFGF and Bcl-2 in benign prostatic hyperplasia].
Song W; Li DY; Yuan HC; Gu ZH; Shao JL; Wang X
Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(2):104-7. PubMed ID: 26792691
[TBL] [Abstract][Full Text] [Related]
34. Pentraxin 3, long expression in mononuclear cells of patients with acute coronary syndrome: Correlation with C-reactive protein and matrix metalloproteinase-9 levels.
Ma R; Zhang W; Wang T; He X; Huang Z; Zhu J; Yao Z
J Int Med Res; 2014 Jun; 42(3):677-83. PubMed ID: 24709882
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia.
Hamdy FC; Fadlon EJ; Cottam D; Lawry J; Thurrell W; Silcocks PB; Anderson JB; Williams JL; Rees RC
Br J Cancer; 1994 Jan; 69(1):177-82. PubMed ID: 7506923
[TBL] [Abstract][Full Text] [Related]
36. Modulation of complement activation by pentraxin-3 in prostate cancer.
Stallone G; Netti GS; Cormio L; Castellano G; Infante B; Pontrelli P; Divella C; Selvaggio O; Spadaccino F; Ranieri E; Sanguedolce F; Pennella A; Gesualdo L; Carrieri G; Grandaliano G
Sci Rep; 2020 Oct; 10(1):18400. PubMed ID: 33110136
[TBL] [Abstract][Full Text] [Related]
37. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
[TBL] [Abstract][Full Text] [Related]
39. Strong impact of nocturia on sleep quality in patients with lower urinary tract symptoms.
Doo SW; Lee HJ; Ahn J; Kim JH; Yun JH; Yang WJ; Song YS
World J Mens Health; 2012 Aug; 30(2):123-30. PubMed ID: 23596599
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion.
Stearns ME; Rhim J; Wang M
Clin Cancer Res; 1999 Jan; 5(1):189-96. PubMed ID: 9918218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
